Navigation Links
The 4th Annual BIO Investor Forum to Webcast Alexza's Corporate Presentation
Date:10/3/2007

PALO ALTO, Calif., Oct. 3 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that its corporate presentation will be webcast live during the 4th Annual BIO Investor Forum on Thursday, October 11, 2007 at 4:30 p.m. Eastern Time. The presentation will be webcast from The Palace Hotel, San Francisco and may be accessed under the Investor Relations tab at http://www.alexza.com or http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=ALXA&item_id=16576 53. The presentation will be archived for 14 days.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. The Company has six product candidates in development; AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic and bipolar disorder patients, AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches, AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder, AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches, AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain and AZ-007 (Staccato zaleplon) for the treatment of sleep disorder in patients who have difficulty falling asleep.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K/A for the year ended December 31, 2006, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. NameProtect releases annual list of top trademarkers
2. Doyle says new contracts saving state more than $16 million annually
3. Department of Commerce offers up to $1 million annually to aid tech entrepreneurs
4. Annual Bioethics Forum to explore genetic testing
5. Annual Conference Honors Tech Grant Winners
6. Venture Investors early-stage fund grows to $115 million
7. Investor warns of angel-venture funding gap
8. Brazilian bio-industry should impress American investors
9. Investors raise $25 million for biodiesel plant
10. Bio-energy and cleantech grab attention of investors
11. Venture Investors to open Michigan office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Summit for Stem Cell has received a $250,000 ... patient-specific stem cell therapy for the treatment of Parkinson’s disease. The Summit research project ... The Scripps Research Institute in San Diego, CA. , The aim of ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... biotechnology acceleration company reports the Company,s CEO  was ... capital titled Accelerators Enter When VCs Fear To ... Life Science Leader magazine is an ... work for everything from emerging biotechs to Big ...
(Date:4/28/2016)... ... April 28, 2016 , ... Morris Midwest ( ... for regional manufacturers at its Maple Grove, Minnesota technical center, May 11-12. ... and Trumpf. Almost 20 leading suppliers of tooling, accessories, software and other ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... screen mobile devices with fingerprint recognition for secure access, voice recognition for hands-free ... few ways consumers are interacting with biometrics technology today. But if they ...
Breaking Biology Technology:
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
(Date:3/21/2016)... Unique technology combines v ... security   Xura, Inc. ... digital communications services, today announced it is working alongside ... customers, particularly those in the Financial Services Sector, the ... within a mobile app, alongside, and in combination with, ...
(Date:3/15/2016)... March 15, 2016 Yissum Research Development ... technology-transfer company of the Hebrew University, announced today the ... sensing technology of various human biological indicators. Neteera Technologies ... million from private investors. ... the detection of electromagnetic emissions from sweat ducts, enables ...
Breaking Biology News(10 mins):